Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04698915 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
A Phase 2 study, sponsored by Galera Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
NCT04698915 is a Phase 2 study that was terminated before completion, run by Galera Therapeutics. The registered enrollment target is 177 participants.
The verdict
NCT04698915, a Phase 2 study, was terminated before completion, sponsored by Galera Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
Study Summary
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic
Interventions
- DRUG Placebo
- DRUG Drug GC4711
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04698915
The ClinicalTrials.gov registry entry for NCT04698915 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galera Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04698915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04698915 about?
NCT04698915 is a clinical study titled "Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer". GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic
What is the current status of trial NCT04698915?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2021-05-07. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT04698915?
The interventions under investigation include: Placebo (DRUG), Drug GC4711 (DRUG).
Who is sponsoring clinical trial NCT04698915?
This trial is sponsored by Galera Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.